AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Treace Medical Concepts Faces Securities Fraud Lawsuit, Investors Must Act by June 10, 2025.
ByAinvest
Monday, Jun 9, 2025 4:37 am ET1min read
TMCI investors have a final opportunity to lead a class action lawsuit against Treace Medical Concepts, Inc. for violating securities laws. The lawsuit alleges the company made false and misleading statements about its Lapiplasty 3D Bunion Correction System, leading to a decline in revenue and the need to accelerate plans to offer an osteotomy alternative. Investors who purchased the company's securities between May 8, 2023 and May 7, 2024 are encouraged to contact the Schall Law Firm before June 10, 2025.
Title: TMCI Investors: Last Chance to Lead Class Action Lawsuit Against Treace Medical Concepts, Inc.Investors who purchased Treace Medical Concepts, Inc. (TMCI) securities between May 8, 2023 and May 7, 2024 have a final opportunity to lead a class action lawsuit against the company. The lawsuit alleges that TMCI made false and misleading statements about its flagship product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue and the need to accelerate plans to offer an osteotomy alternative. Investors are encouraged to contact the Schall Law Firm before the June 10, 2025 deadline to participate in the lawsuit.
The lawsuit, filed by the Schall Law Firm, alleges that TMCI made materially false and/or misleading statements and failed to disclose adverse facts about its business, operations, and prospects. Specifically, the complaint alleges that TMCI failed to disclose the impact of competition on the demand for and utilization of the Lapiplasty product, resulting in a decline in revenue. The company was also accused of accelerating its plans to offer a product that was an alternative to osteotomy due to the competitive pressures.
Investors who were adversely affected by these alleged securities frauds are encouraged to join the class action lawsuit. There is no cost to participate, and the Schall Law Firm will represent investors on a contingency fee basis. This means that the firm will only be reimbursed for out-of-pocket expenses and attorneys’ fees if the lawsuit is successful.
The Schall Law Firm has a proven track record of representing investors in securities fraud class actions and shareholder derivative suits. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders and built a reputation for winning high-stakes cases.
Investors who wish to join the class action lawsuit should contact the Schall Law Firm before the June 10, 2025 deadline. The firm can be reached at [email address] or [phone number]. Investors can also visit the firm's website for more information and to submit a claim.
References
[1] https://www.ainvest.com/news/navigating-treace-medical-lawsuit-implications-stock-valuation-investor-strategy-2506/
[2] https://www.globenewswire.com/news-release/2025/06/04/3093953/9788/en/TMCI-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Treace-Medical-Concepts-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html
[3] https://www.morningstar.com/news/pr-newswire/20250606ny04516/lost-money-on-treace-medical-concepts-inctmci-join-class-action-suit-seeking-recovery-contact-levi-korsinsky
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet